Physician profile
Sandra Renae Evans
NPI 1114680097
$415.17
in general payments reported to CMS, 2019-2025
12 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $38.64 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $112.97 | 2025 | Auvelity |
| Abbvie INC. | $53.79 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $38.64 | 2023 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $35.27 | 2025 | Zoryve |
| Amgen INC. | $35.06 | 2025 | Repatha, Otezla |
| Corcept Therapeutics | $24.48 | 2025 | Korlym |
| Exact Sciences Corporation | $24.44 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $23.81 | 2025 | Rexulti |
| Novo Nordisk INC | $17.98 | 2025 | Ozempic |
| Lilly USA, LLC | $17.69 | 2025 | Mounjaro |
| Pfizer INC. | $16.70 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $14.34 | 2025 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.